KIM vs NKTR · P/E 27, rev $1.11B vs rev $21.0M
Kimco Realty Corporation (KIM) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Kimco Realty Corporation (KIM) is a reit - retail company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported KIM revenue for 2026-06-30 was $1.11B. Net income was $318.2M. Revenue was up 98.7% from 2026-03-31 to 2026-06-30. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
KIM currently screens at market cap $16.03B and trailing P/E 27.3. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the KIM and NKTR stock pages for the full models.
Not investment advice.